Allogene Therapeutics Inc —— 资产负债表 (NASDAQ:ALLO) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 1.23 B1.04 B817.08 M642.84 M548.71 M415.9 M 负债总额 148.21 M122.23 M151.21 M130.6 M126.53 M123.36 M 权益总额 1.08 B916.41 M665.87 M512.23 M422.18 M292.54 M 负债及股东权益总额 1.23 B1.04 B817.08 M642.84 M548.71 M415.9 M 总债务 50.38 M————— 净债务 -949.62 M—————

新闻

ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study

Company News for Apr 14, 2026

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow (NASDAQ:ALLO) 2026-04-14

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript

Allogene: Early ALPHA3 Data Suggests Potential Paradigm Shift For Cema-Cel In LBCL

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Citizens重申Allogene股票评级,看好其管线进展

Citizens reiterates Allogene stock rating on pipeline progress

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript

Allogene Therapeutics第四季度业绩超预期

Earnings call transcript: Allogene Therapeutics beats Q4 2025 EPS forecast

Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus